Delving into the Latest Updates on Baiaoxin Management (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Nervous System Diseases

Immune System Diseases

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	1

Top 5 Target	Count

CGRP receptor(Calcitonin gene-related peptide type 1 receptor)	1

主要目的：通过测量给药后 2 小时的疼痛消除情况，评价 Rimegepant 相比安慰剂在青少年人群（≥ 12 岁至 < 18 岁）偏头痛急性期治疗中的疗效。次要目的：通过测量给药后 2 小时的疼痛消除情况，评价 Rimegepant 相比安慰剂在儿童和青少年（≥ 6 岁至 < 18 岁）合并人群偏头痛急性期治疗中的疗效。

[Translation]

Primary objective: To evaluate the efficacy of rimegepant compared to placebo in the acute treatment of migraine in adolescents (≥ 12 years to < 18 years) by measuring pain freedom 2 hours after dosing. Secondary objective: To evaluate the efficacy of rimegepant compared to placebo in the acute treatment of migraine in a combined population of children and adolescents (≥ 6 years to < 18 years) by measuring pain freedom 2 hours after dosing.

Start Date10 Nov 2022

Sponsor / Collaborator

Biohaven Pharmaceutical Ireland DAC

[+2]

CTR20213162

/ CompletedPhase 1

一项在中国健康受试者中评Troriluzole（BHV-4157）280mg单次和多次给药后的安全性、耐受性和药代动力学特征的I期、随机、双盲、安慰剂对照研究

[Translation] A Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of Troriluzole (BHV-4157) 280 mg after single and multiple doses in healthy Chinese subjects

主要目的：评估在中国健康受试者中单次（280 mg）和多次（280 mg/日，连续5天）给药Troriluzole后的安全性和耐受性。次要目的：评估在中国健康受试者中单次（280 mg）和多次（280 mg/日，连续5天）给药Troriluzole后利鲁唑的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of troriluzole after single (280 mg) and multiple (280 mg/day, 5 consecutive days) administration in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of riluzole after single (280 mg) and multiple (280 mg/day, 5 consecutive days) administration of troriluzole in healthy Chinese subjects.

Start Date03 Mar 2022

Sponsor / Collaborator

Bioshin Ltd.

[+2]

100 Clinical Results associated with Baiaoxin Management (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Baiaoxin Management (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with Baiaoxin Management (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Baiaoxin Management (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Other

Login to view more data